Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

2019 meeting of the global virus network.

Akkina R, Garry R, Bréchot C, Ellerbrok H, Hasegawa H, Menéndez-Arias L, Mercer N, Neyts J, Romanowski V, Segalés J, Vahlne A.

Antiviral Res. 2019 Dec;172:104645. doi: 10.1016/j.antiviral.2019.104645. Epub 2019 Nov 4. Review.

PMID:
31697957
2.

2018 international meeting of the Global Virus Network.

Brechot C, Bryant J, Endtz H, Garry RF, Griffin DE, Lewin SR, Mercer N, Osterhaus A, Picot V, Vahlne A, Verjans GMGM, Weaver S.

Antiviral Res. 2019 Mar;163:140-148. doi: 10.1016/j.antiviral.2019.01.013. Epub 2019 Jan 25. Review.

PMID:
30690044
3.

Identification and application of self-binding zipper-like sequences in SARS-CoV spike protein.

Zhang SM, Liao Y, Neo TL, Lu Y, Liu DX, Vahlne A, Tam JP.

Int J Biochem Cell Biol. 2018 Aug;101:103-112. doi: 10.1016/j.biocel.2018.05.012. Epub 2018 May 22.

PMID:
29800727
4.

2016 International meeting of the Global Virus Network.

Akkina R, Ellerbrok H, Hall W, Hasegawa H, Kawaguchi Y, Kleanthous H, McSweegan E, Mercer N, Romanowski V, Sawa H, Vahlne A.

Antiviral Res. 2017 Jun;142:21-29. doi: 10.1016/j.antiviral.2017.03.005. Epub 2017 Mar 16.

PMID:
28315708
5.

How Zika virus made the transition from being a virtually unknown virus to a high-profile public health threat.

Vahlne A.

Acta Paediatr. 2016 Jul;105(7):728-9. doi: 10.1111/apa.13436. No abstract available.

PMID:
27272625
6.
7.

Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops.

Moscoso CG, Xing L, Hui J, Hu J, Kalkhoran MB, Yenigun OM, Sun Y, Paavolainen L, Martin L, Vahlne A, Zambonelli C, Barnett SW, Srivastava IK, Cheng RH.

Sci Rep. 2014 Nov 14;4:7025. doi: 10.1038/srep07025.

8.

Anti-human immunodeficiency virus type 1 agent alpha-hydroxy glycineamide enters the target cells via a mechanism of passive diffusion.

Youssefi M, Vahlne A.

J Pharm Pharmacol. 2014 Oct;66(10):1388-93. doi: 10.1111/jphp.12269. Epub 2014 Apr 29.

PMID:
24780097
9.

Human serum increases CD4 recycling to plasma membranes of in-vitro cultured cells.

Perdomo MF, Vahlne A.

AIDS. 2013 Jun 19;27(10):1680-2. doi: 10.1097/QAD.0b013e328362de8c. No abstract available.

PMID:
23863352
10.

HIV-1 Tat protein induces viral internalization through Env-mediated interactions in dose-dependent manner.

Poon S, Moscoso CG, Yenigun OM, Kolatkar PR, Cheng RH, Vahlne A.

AIDS. 2013 Sep 24;27(15):2355-64. doi: 10.1097/01.aids.0000432452.83604.59.

PMID:
23842123
11.

Putative role of Tat-Env interaction in HIV infection.

Poon S, Moscoso CG, Xing L, Kan E, Sun Y, Kolatkar PR, Vahlne AG, Srivastava IK, Barnett SW, Cheng RH.

AIDS. 2013 Sep 24;27(15):2345-54. doi: 10.1097/01.aids.0000432453.60733.b2.

PMID:
23835500
12.

Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.

Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L, Sällberg M.

Mol Ther. 2013 Sep;21(9):1796-805. doi: 10.1038/mt.2013.119. Epub 2013 Jun 11.

13.

Human serum protein enhances HIV-1 replication and up-regulates the transcription factor AP-1.

Perdomo MF, Hosia W, Jejcic A, Corthals GL, Vahlne A.

Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17639-44. doi: 10.1073/pnas.1206893109. Epub 2012 Oct 9.

14.

HIV inhibition by CD4 and CCR5-derived glycopeptides.

Perdomo MF, Sällberg M, Vahlne A.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1052-8. doi: 10.1089/AID.2012.0009. Epub 2012 Jun 12.

PMID:
22559037
15.

Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding.

Moscoso CG, Sun Y, Poon S, Xing L, Kan E, Martin L, Green D, Lin F, Vahlne AG, Barnett S, Srivastava I, Cheng RH.

Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6091-6. doi: 10.1073/pnas.1016113108. Epub 2011 Mar 28.

16.

GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway.

Jejcic A, Höglund S, Vahlne A.

Retrovirology. 2010 Mar 15;7:20. doi: 10.1186/1742-4690-7-20.

17.

Small molecule targets Env for endoplasmic reticulum-associated protein degradation and inhibits human immunodeficiency virus type 1 propagation.

Jejcic A, Daniels R, Goobar-Larsson L, Hebert DN, Vahlne A.

J Virol. 2009 Oct;83(19):10075-84. doi: 10.1128/JVI.01700-08. Epub 2009 Jul 29.

18.

A historical reflection on the discovery of human retroviruses.

Vahlne A.

Retrovirology. 2009 May 1;6:40. doi: 10.1186/1742-4690-6-40.

19.

Isolation and characterization of a small antiretroviral molecule affecting HIV-1 capsid morphology.

Abdurahman S, Végvári A, Levi M, Höglund S, Högberg M, Tong W, Romero I, Balzarini J, Vahlne A.

Retrovirology. 2009 Apr 8;6:34. doi: 10.1186/1742-4690-6-34.

20.

Neutralization of HIV-1 by redirection of natural antibodies.

Perdomo MF, Levi M, Sällberg M, Vahlne A.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12515-20. doi: 10.1073/pnas.0805777105. Epub 2008 Aug 21.

21.

Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity.

Abdurahman S, Végvári A, Youssefi M, Levi M, Höglund S, Andersson E, Horal P, Svennerholm B, Balzarini J, Vahlne A.

Antimicrob Agents Chemother. 2008 Oct;52(10):3737-44. doi: 10.1128/AAC.00265-08. Epub 2008 Jul 21.

23.
24.
25.

Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide.

Andersson E, Horal P, Jejcic A, Höglund S, Balzarini J, Vahlne A, Svennerholm B.

Antimicrob Agents Chemother. 2005 Jan;49(1):40-4.

26.

Selected amino acid substitutions in the C-terminal region of human immunodeficiency virus type 1 capsid protein affect virus assembly and release.

Abdurahman S, Höglund S, Goobar-Larsson L, Vahlne A.

J Gen Virol. 2004 Oct;85(Pt 10):2903-13.

PMID:
15448352
27.

Obligatory involvement of CD26/dipeptidyl peptidase IV in the activation of the antiretroviral tripeptide glycylprolylglycinamide (GPG-NH(2)).

Balzarini J, Andersson E, Schols D, Proost P, Van Damme J, Svennerholm B, Horal P, Vahlne A.

Int J Biochem Cell Biol. 2004 Sep;36(9):1848-59.

PMID:
15183349
28.

No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide.

Andersson E, Horal P, Vahlne A, Svennerholm B.

Antiviral Res. 2004 Feb;61(2):119-24.

PMID:
14670585
29.

Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner.

Naghavi MH, Nowak P, Andersson J, Sönnerborg A, Yang H, Tracey KJ, Vahlne A.

Virology. 2003 Sep 15;314(1):179-89.

30.

Tripeptide interference with human immunodeficiency virus type 1 morphogenesis.

Höglund S, Su J, Reneby SS, Végvári A, Hjertén S, Sintorn IM, Foster H, Wu YP, Nyström I, Vahlne A.

Antimicrob Agents Chemother. 2002 Nov;46(11):3597-605.

31.

MCEF, the newest member of the AF4 family of transcription factors involved in leukemia, is a positive transcription elongation factor-b-associated protein.

Estable MC, Naghavi MH, Kato H, Xiao H, Qin J, Vahlne A, Roeder RG.

J Biomed Sci. 2002 May-Jun;9(3):234-45.

PMID:
12065898
32.

Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1.

Maijgren-Steffensson C, Sönnerborg A, Vahlne A, Britton S, Larsson S, Ahrlund-Richter L.

Mol Ther. 2001 Apr;3(4):531-5.

33.

The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.

Su J, Naghavi MH, Jejcic A, Horal P, Furuta Y, Wu YP, Li SL, Hall WW, Goobar-Larsson L, Svennerholm B, Vahlne A.

J Hum Virol. 2001 Jan-Feb;4(1):8-15.

PMID:
11213934
34.

The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.

Su J, Andersson E, Horal P, Naghavi MH, Palm A, Wu YP, Eriksson K, Jansson M, Wigzell H, Svennerholm B, Vahlne A.

J Hum Virol. 2001 Jan-Feb;4(1):1-7.

PMID:
11213928
36.

Real-time monitoring of cytomegalovirus infections after stem cell transplantation using the TaqMan polymerase chain reaction assays.

Yun Z, Lewensohn-Fuchs I, Ljungman P, Vahlne A.

Transplantation. 2000 Apr 27;69(8):1733-6.

PMID:
10836392
37.

Coreceptor usage of HIV-1 after deletion of Gly317-Pro318-Gly319 motif in the gp120 V3 loop.

Su J, Vahlne A.

AIDS. 2000 Jan 7;14(1):91-2. No abstract available.

PMID:
10714573
38.

Deletion of the GPG motif in the HIV type 1 V3 loop does not abrogate infection in all cells.

Su J, Palm A, Wu Y, Sandin S, Höglund S, Vahlne A.

AIDS Res Hum Retroviruses. 2000 Jan 1;16(1):37-48.

PMID:
10628815
39.

Long terminal repeat promoter/enhancer activity of different subtypes of HIV type 1.

Naghavi MH, Schwartz S, Sönnerborg A, Vahlne A.

AIDS Res Hum Retroviruses. 1999 Sep 20;15(14):1293-303.

PMID:
10505678
40.

No association of HIV type 1 long terminal repeat sequence pattern with long-term nonprogression and in vivo viral replication levels in European subjects.

Visco-Comandini U, Yun Z, Vahlne A, Sönnerborg A.

AIDS Res Hum Retroviruses. 1999 May 1;15(7):609-17.

PMID:
10331439
41.

DNA sequence of the long terminal repeat of human immunodeficiency virus type 1 subtype A through G.

Naghavi MH, Salminen MO, Sönnerborg A, Vahlne A.

AIDS Res Hum Retroviruses. 1999 Mar 20;15(5):485-8. No abstract available.

PMID:
10195759
42.

HIV-1 nef mutations and clinical long-term nonprogression. A molecular epidemiology study.

Visco-Comandini U, Yun Z, Paganelli R, Orlandi P, Salotti A, Johansson B, Vahlne A, Sönnerborg A.

J Hum Virol. 1998 Jul-Aug;1(5):320-7.

PMID:
10195259
43.

Increased serum concentrations of interleukin-2 receptor in the first trimester in women who later developed severe preeclampsia.

Eneroth E, Remberger M, Vahlne A, Ringden O.

Acta Obstet Gynecol Scand. 1998 Jul;77(6):591-3.

PMID:
9688233
44.

Quantification of HIV-1 proviral DNA from peripheral blood mononuclear cells using a high throughput four-competitor competitive PCR.

Comandini UV, Sönnerborg A, Vahlne A, Yun Z.

J Virol Methods. 1997 Dec;69(1-2):171-80.

PMID:
9504762
45.
47.

Identification of cross-reactive antigenic target regions for HIV type 1-specific antibody-dependent cellular cytotoxicity.

Broliden K, Von Gegerfelt A, Persson C, Horal P, Svennerholm B, Wahren B, Björling E, Vahlne A.

AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1699-702.

PMID:
8959246
48.

mtDNA variation indicates Mongolia may have been the source for the founding population for the New World.

Merriwether DA, Hall WW, Vahlne A, Ferrell RE.

Am J Hum Genet. 1996 Jul;59(1):204-12.

49.

A novel ribozyme target site located in the HIV-1 nef open reading frame.

Larsson S, Hotchkiss G, Su J, Kebede T, Andäng M, Nyholm T, Johansson B, Sönnerborg A, Vahlne A, Britton S, Ahrlund-Richter L.

Virology. 1996 May 1;219(1):161-9.

50.

Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

Lycke J, Svennerholm B, Hjelmquist E, Frisén L, Badr G, Andersson M, Vahlne A, Andersen O.

J Neurol. 1996 Mar;243(3):214-24.

PMID:
8936350

Supplemental Content

Loading ...
Support Center